Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Subscribe To Our Newsletter & Stay Updated